The Industry That is Depending on Science and Regulation to Grow

Yuran Li, Director, MS Commercial Strategies, Alternative Biomedical Solutions (ABS), is a biochemist by training. Still, his fascinations with physics, math, and probability have led him down some interesting paths, including some stints in the professional poker world. Lucky for ABS, he chose the science route.

Cannabis is a schedule 1 drug classification by the U.S. Federal government. As more and more states legalize it, there is a growing need for reliable testing to ensure the safety and potency of cannabis products. ABS is one of the pioneers in cannabis method development and testing. Li spoke with Jason Claybrook on some of ABS’s activities surrounding Cannabis.

Any product that people consume goes through testing to ensure their safety. “Cannabis is unique in that it’s ultimately a weed,” Li said. And it can prove quite a challenge to cultivate because the plant can soak up a lot of pesticides and other elements used for pest control. “Additionally, the Cannabis plant itself also uptakes quite a lot of heavy metals, things like arsenic and lead.” Accumulation of these pollutants can harm humans, so accurate testing is essential.

Some of the testing ABS does on Cannabis is to look for micro toxins, like mold and soil pollutants. And from a marketing and regulatory standpoint, they test for potency. In some cases, testing can help ensure that a strain grown for CBD does not contain THC. One challenge Li cautioned is every state has different guidelines, and it is essential to understand the laws governing each state where Cannabis sales are allowed.

Another aspect of lab testing that is becoming more and more important for Cannabis is label testing. As with craft beers and whiskey, labels need to back up their product’s claims. Testing ensures the strain offered on the label is the strain received by the consumer.

More Stories Like This:

Breaking through ‘Pilot Purgatory’ in Innovating New Solutions

Is Cryptocurrency and Its Tech Infrastructure Ready for a Revolution?

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More